Healthcare AI devices lacking publicly available clinical study information may be more likely to be recalled, according to a June 11 study published in JAMA Network Open. Researchers said the findings emphasize the importance of clinical validation and postmarket monitoring for AI-enabled medical devices.
Here are four notes from the study:
- Researchers examined 903 FDA-authorized AI-enabled medical devices approved between 1995 and 2024. Of those, 43 devices, or 4.8%, were recalled after a median of 458 days.
- Devices with missing information on supporting clinical studies were associated with a higher hazard of recall than devices backed by published clinical studies.
- Devices flagged in the CORE-MD postmarket surveillance tool and those identified in multiple surveillance databases showed higher recall risk than devices without reported safety signals.
- Incorrect use of an AI-enabled device was associated with a higher recall hazard. Researchers also found software-related problems and concerns involving device outputs were among the most frequently reported issues.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.